Together, we can help end the HIV epidemic for everyone, everywhere
Meet our collaborators who make our work possible
A Doctor Sowing Seeds of Hope.
When a world-renowned hospital for HIV treatment and prevention was faced with barriers to patient care, one doctor used his voice to improve the quality of care for its future.
Dr. Moussa Seydi worked at Fann Hospital in Senegal for 15 years before rising to become the Head of Infectious and Tropical Diseases. Unfortunately, over this time, the hospital fell into disrepair due to natural disasters. As a leader, his mission was to restore Fann Hospital with new facilities to match their exemplary standards of care.
Gilead and Dr. Seydi had previously combined efforts as a part of the African Society of Infectious Disease, so when Dr. Seydi reached out about his mission, Gilead swiftly supported the cause with a grant to kickstart his project.
With access to more resources and additional support through capturing the attention of the Senegalese government, Dr. Seydi was able to design a new, state-of-the-art facility.
Follow @GileadSciences for updates on this story and more.
Ending the epidemic for everyone, everywhere
Decades of scientific innovation, partnership, and advocacy helped transform HIV from a fatal diagnosis to one that could be managed and prevented. Now, we’ll continue to support the wellness of all people impacted by HIV until the virus is eliminated.
Developing innovations
We developed the first HIV single tablet regimen and the first oral therapy to prevent HIV, but we’re still researching new strategies.
Advancing equitable care
We’ve forged partnerships to expand access to our life-saving medicines and continue to help facilitate treatment options.
Transformative collaboration
Pervasive prejudice perpetuates stigma surrounding HIV. We’re working closely with communities to fight discrimination.
Gilead’s commitment to ending the epidemic
Where we’ve been
Gilead created the first single-tablet HIV treatment and the first medicines to reduce the risk of infection.1 Gilead is proud to be recognized as the largest private funder of non-profit HIV programs in the U.S., and third largest in the world to date.2
Where we are
We’ve been teaming up with organizations to improve care globally. We’ve launched initiatives like COMPASS, RADIAN®, and Zeroing In™, while growing existing programs like AIDSVu. We are even raising awareness of HIV in Japan with a comic book.
Where we’re headed
We are adapting our approach to HIV treatment and prevention to better support people and communities impacted by the disease. We’re also continuing to fight to end the HIV epidemic, with the goal of achieving a functional cure for HIV.
Working Together to End the Epidemic: Guided by the Voices on the Ground.
Join us for a presentation
Monday, August 1st • 8am–9am
We’ll be showcasing how innovation, resilience, and community-led initiatives will help us meet challenges in ending the global HIV epidemic.
See our press release for more details.
Our presenter
Shonda Jones
Principal Investigator for the Gilead COMPASS Faith Coordinating Centre at Wake Forest University
Featuring each of our collaborator stories, followed by a panel discussion with Michael Angelo Marquez, MD; Jean Robert, MD; and Abby Charles, MPH; moderated by Alex Kalomparis, Gilead Senior Vice President, Public Affairs.